

Amiodarone Infusion

Indication	Broad-spectrum anti-arrhythmic. Used in AF, VF, VT and paroxysmal SVT.																				
Dose	<p>Non-arrest cardioversion: 300mg loading infusion, followed by maintenance infusion of 900mg over 23-24hr.</p> <p>Maintenance IV doses of maximum 1.2g in 24 hours can be given, preferably via a central line</p>																				
Preparation	<p>For administration through peripheral vein or central line</p> <p>IV Loading Dose</p> <ol style="list-style-type: none"> 1. Draw up 300mg of amiodarone (50mg/ml) using a filter needle 2. Add to 250ml glucose 5% and mix well 3. Infuse over 60mins <p>Maintenance infusion</p> <ol style="list-style-type: none"> 1. Draw up 900mg of amiodarone (50mg/ml) using a filter needle 2. Add to 500ml glucose 5% and mix well 3. Infuse over 23-24 hours 																				
Administration	Amiodarone can cause thrombophlebitis if infused for prolonged periods into a peripheral vein. A large peripheral vein (e.g. antecubital fossa) should be used where no central access is possible. Infuse via a Baxter pump. Switch to oral route as soon as available.																				
Shelf-life	24hours at room temperature																				
Common Compatibility Issues	Amiodarone is incompatible with sodium chloride 0.9% and is generally infused using a dedicated lumen for the duration of the infusion. Use of sodium chloride 0.9% for flushing doses is acceptable.																				
Additional information	<p>A patient can be considered to have been loaded with amiodarone when they have received a cumulative dose of 7-10g of amiodarone (either IV or enterally) and then the dose needs to be decreased to 200mg OD enterally.</p> <p>Amiodarone has multiple severe interactions with medications. Please check and adjust other medication doses with long term treatment.</p>																				
Sample Label	<table border="1" style="width: 100%; background-color: #ffff00;"> <tr> <th colspan="4" style="text-align: center;">DRUGS ADDED TO THIS INFUSION</th> </tr> <tr> <td colspan="3">PATIENT <i>A. Patient (A. Number)</i></td> <td>WARD <i>CCU</i></td> </tr> <tr> <td>DRUG <i>Amiodarone In 250ml Glucose 5%</i></td> <td>AMOUNT <i>300mg</i></td> <td>ADD BY</td> <td>CHECKED BY</td> </tr> <tr> <td>DATE ADDED TIME ADDED</td> <td>EXP. DATE EXP. TIME</td> <td colspan="2">BATCH No.</td> </tr> <tr> <td colspan="4" style="text-align: center;">DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS</td> </tr> </table>	DRUGS ADDED TO THIS INFUSION				PATIENT <i>A. Patient (A. Number)</i>			WARD <i>CCU</i>	DRUG <i>Amiodarone In 250ml Glucose 5%</i>	AMOUNT <i>300mg</i>	ADD BY	CHECKED BY	DATE ADDED TIME ADDED	EXP. DATE EXP. TIME	BATCH No.		DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS			
DRUGS ADDED TO THIS INFUSION																					
PATIENT <i>A. Patient (A. Number)</i>			WARD <i>CCU</i>																		
DRUG <i>Amiodarone In 250ml Glucose 5%</i>	AMOUNT <i>300mg</i>	ADD BY	CHECKED BY																		
DATE ADDED TIME ADDED	EXP. DATE EXP. TIME	BATCH No.																			
DISCONTINUE IF CLOUDINESS OR PRECIPITATE DEVELOPS																					

Written by Kayleigh Lehal – Senior Rotational Pharmacist August 2016
Reviewed by Hester Smail (Advanced Pharmacist Cardiology) November 2023

Approved by Dr Damian Kelly – Lead Cardiologist
Medical Division - 18/5/18

For review November 2026

References

Summary of Product Characteristics. <http://www.emc.medicines.org.uk>. Accessed November 2023

ASHP Injectable Drug Information Accessed November 2023

Brayfield A (ed), Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press <<http://www.medicinescomplete.com/>> (accessed November 2023).

AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. Journal of the American College of Cardiology; 2014; 64 (21)